Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 4/20 | 0.43 |
| ▸ | PGR | P06401 | 3/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 4/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | CBX7 | O95931 | 1/20 | 0.36 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.36 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.36 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2471501 | 0.87 | CYP46A1 (0.38) | AKR1B1PGRIDO1MAPTHTR7 | |
| SCHEMBL9542468 | 0.86 | PGR (0.40) | PGRIDO1MAPTHTR7MEN1 | |
| SCHEMBL9539722 | 0.85 | AKR1B1 (0.50) | AKR1B1PGRIDO1MAPTHTR7 | |
| SCHEMBL21939397 | 0.84 | AKR1B1 (0.41) | AKR1B1PGRIDO1MAPTHTR7 | |
| SCHEMBL9539014 | 0.83 | AKR1B1 (0.40) | AKR1B1PGRIDO1MAPTHTR7 | |
| SCHEMBL11388713 | 0.83 | MDM2 (0.46) | AKR1B1IDO1CBX7CDYL2CDYL | |
| SCHEMBL9539751 | 0.80 | AKR1B1 (0.38) | AKR1B1PGRIDO1MAPTHTR7 | |
| SCHEMBL2467289 | 0.80 | PGR (0.40) | AKR1B1PGRIDO1HTR7 | |
| SCHEMBL2469599 | 0.79 | CYP46A1 (0.39) | AKR1B1PGRIDO1MAPTHTR7 | |
| SCHEMBL9539047 | 0.78 | AKR1B1 (0.48) | AKR1B1PGRIDO1MAPTHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210128537-A1 | T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | PRAXIS PREC MEDICINES INC (US) | 2021-05-06 | — | — | US | disclosed |
| US-20210038589-A1 | USES, COMPOSITIONS AND METHODS | FISAHN ANDRE (SE) | 2021-02-11 | — | — | US | disclosed |
| WO-2018118101-A1 | T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| EP-1553946-A4 | ENHANCEMENT OF SLEEP WITH T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO INC (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20060003985-A1 | Enhancement of sleep with t-type calcium channel antagonists | RENGER JOHN J | 2006-01-05 | — | — | US | disclosed |
| EP-1553946-A2 | ENHANCEMENT OF SLEEP WITH T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck & Co., Inc. (US) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004035000-A2 | ENHANCEMENT OF SLEEP WITH T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210038589-A1 | USES, COMPOSITIONS AND METHODS | APP, CACNA1G, CACNA1B | AKR1B1 2384/4885PGR 4148/4885IDO1 3399/4885 |
| US-20210128537-A1 | T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | CACNA1G, CACNA1H, CACNA1I | AKR1B1 3949/4885PGR 4675/4885IDO1 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.